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Abstract
Background: The identification and management of antiretroviral therapy failure is a key
challenge for HIV/AIDS programs in resource-limited settings. In Ethiopia diagnosing
treatment failure and monitoring patient response with routine viral load, is not feasible.
Recently, it has been started targeted viral load monitoring to confirm treatment failure in
hospital settings. However factors lead to treatment failure is not well understood and well-
studied.
Objective: To identify determinants of antiretroviral virologic treatment failure in Gondar
University Hospital.
Methods: An unmatched case control study was conducted at Gondar University Hospital
using record review. Total sample size was 306 (153 cases and 153 controls). The study was
done from May to June. Bivariate analysis was done and all explanatory variables associated
with treatment failure with P<.0.2 were entered in to multivariable logistic regression analysis
using back ward stepwise likelihood ratio method to identify independent predictors to identify
independent predictors.
Result: One hundred fifty three cases and One hundred fifty three controls were included in
the study. Poor adherence (Adjusted odds ratio (AOR), 29.0, 95% confidence interval (CI),
11.3 - 75.4), recent clusters of differentiation cell count (CD4<200 cells/µl (AOR, 13.8, 95%
CI, 5.7 - 33), age (25-34)(AOR, 8.8, 95%, CI, 2-31.) and unmarried(AOR, .33, 95% CI, .12 -
.87) were all independently associated with antiretroviral virologic treatment failure.
Conclusion and Recommendation: The independent associated factors for
antiretroviral virologic treatment failure were; recent cd4 cell count lower than 200 cell/µl,
history of poor adherence for ART, age<34years and unmarried. There for Health
professionals should pay special attention for the risk group identified.
Keywords: antiretroviral therapy, case control study, treatment failure, highly active Anti-
Retro-Viral.
11. Introduction
1.1Statement of the problem
The impact of HIV infection has dramatically been altered with the introduction of antiretroviral
drugs in 1987 and modification by combination treatment, known as highly active antiretroviral
therapy (HAART), in 1996. After three years following the introduction of HAART, mortality,
AIDS-defining diagnoses, and hospitalizations all decreased 60 to 80%(1, 2).
About 20 ARV drugs available of which one injectable and the others are tablets and these
are generally classified as fusion inhibitors, nucleoside –reverse transcriptase inhibitors
(NRTIs),non-nucleosidereversetranscriptase inhibitors (NNRTIs), Integrate inhibitors, and
protease inhibitors (PIs).Resource limited settings use the WHO recommendation 2NRITs +
NNRTIs as first line regimen and 2NRITIs+ PIs as second line treatment regimen (1, 3).
Even though ART dramatically changed the impact of HIV infection, eradication of the virus
cannot be achieved with available antiretroviral (ARV) regimens even when new, potent drugs
are added to a regimen that is already suppressing plasma viral load below the limits of
detection of commercially available assays) (1, 4, 5).
Use of ART has been associated with the development of HIV drug resistance (HIVDR).
Because of the error- prone nature of HIV reverse transcriptase, the virus‟ high mutation rate
in the presence of drug selective pressure, and because of the need for lifelong treatment, it
is anticipated that some degree of HIVDR will occur among populations on treatment even
when appropriate ART regimens are provided and optimal adherence to therapy is
supported(1, 6).
Treatment failure occurs when the anti-HIV medications (HAART) taken can’t control HIV
RNA replication in the body. Based on the monitoring strategies, treatment failure can be
categorized as: virologic failure, immunologic failure, and clinical failure(3, 7, 8).Hence viral
load monitoring and follow-up is not feasible in resource limited settings; clinical and
immunologic criteria have been used to monitor virologic failure which has low sensitivity and
positive predictive. Given that the true magnitude of ART treatment failure was not well known
in resource limited settings. In the absence of virologic monitoring; diagnosis of ART
treatment failure is difficult and many HIV infected patients are died, delayed to switch to
second line treatment and unnecessary switch to coasty second line regimen in resource
2limited settings(5). As WHO 2014 consolidated ART guideline definition, Virologic failure is
viral load >1000c/ml While taking HAART for ≥ 6 months(7, 8).A rate of treatment failure in
WHO-recommended first-line antiretroviral regimens in resource-limited settings was six
percent. The failure rate per hundred year of follow-up ( P100YFUwas 6.08).In Asia 2.55 and
in Africa 7.1(9).
According to HIV Related Estimates and Projections for Ethiopia in 2013, the total number of
patients ever started on treatment was 499,412 out of 822,531 patients. Currently, 1.5 % of
the patients are on 2nd ART line regimens(8).
At the beginning of ART era the rate of treatment failure was high with single or dual therapy,
but in the era of HAART the rate is reduced. But as ART scale-up increases the number of
HIV infected clients risk of treatment failure also increases proportionally(1).
In Ethiopia ART treatment monitoring and follow up is based on the WHO clinical and
immunological criteria to predict virologic failure, and (recently it has started targeted VL
monitoring).Because there is scarcity of information related to Predictors of HIV virologic
treatment failure at Gondar university hospital. This study determines the Predictors of
virologic treatment failure among adult ART patients at Gondar University Hospital
31.2. Literature Review
Risk factor for viroogic failure
A case-control study designed to know the association of pre-existing Minority Drug-Resistant
HIV-1 Variants, Adherence and risk of antiretroviral treatment failure shows that detection of
minority Y181C mutants was Associated with an increased risk of virologic failure in the
setting of recent treatment adherence but not in non-adherent subjects . In adherent patients,
pre-existing minority Y181C mutants more than tripled the risk of virologic failure of first-line
efavirenz-based antiretroviral therapy (13).
Another study done at nine research center  North and South America the presence of
K103N mutation at initiation of therapy was associated with VF in both arms (14).Higher
pretreatment or baseline HIV RNA level, lower baseline CD4 count, Co-morbidities (e.g.,
active substance abuse, psychiatric disease, neuro cognitive deficits), Presence of drug-
resistant virus, Prior treatment failure, and incomplete adherence(1, 3).
A study shows that: higher base line HIV RNA level was found to be a risk factor for virologic
failure(12, 13).
A study in Cameron shows that failure to achieve cd4 count >100cells/mm3 at 6 month was
found to be a risk factor of virologic treatment failure(15).Another study shows immunological
failure with was associated with VF(10).
Another risk factor associated with HIV virologic treatment failure is adherence status.it was
shown by a study done in yawn die, Cameron, pharmacy  refill irregularity was strong
predictor and it was found to be a better alternative tool to monitor virologic outcome(15).
Other factors associated with HIV  virologic treatment  failure were long duration on ART(10,
11),followed in rural follow up centers, those patients who haven’t disclose their HIV status,
were found to be risk factors of HIV virologic  treatment failure (10).
Factors associated with failure to achieve viral suppression at 6-months of second-line ART
were: adherence <80% and viral load >100,000 at the time of treatment failure. The study
demonstrated favorable virological outcomes of the second-line ART in Georgia. Majority of
patients, including IDUs, achieve sustained virological response over 36 month period(16).
Comment [U1]: which study?
4Suboptimal virologic potency (1, 12),prior exposure to suboptimal regimens(12), high pill
burden and/or dosing frequency, adverse drug-drug interactions with concomitant
medications, history of drug substitution(1, 3) history of treatment interruption), pruritic
popular eruption(PPE)(10) were the other risk  factors for HIV virologic treatment failure as
shown by different  literatures in  the world.
the risk factors of treatment failure are generally associated with patient related factor(such as
higher baseline HIV RNA level, lower baseline CD4 count, co-morbidities (e.g., active
substance abuse, psychiatric disease, and neuro-cognitive deficits), presence of drug-
resistant virus, prior treatment failure, and incomplete adherence(1, 3),age <30 years, long
duration on ART(10, 11),followed in rural follow up centers, those patients who haven’t
disclose their HIV status(10)
,and ARV medication related factors(suboptimal virologic potency(1, 12)Prior exposure to
suboptimal regimens(12), high pill burden and/or dosing frequency, adverse drug-drug
interactions with concomitant medications(1, 3) were the other risk  factors for HIV virologic
treatment failure as shown by different  literatures  globally.
a cross-sectional study to compare factors associated with raised viral load between patients
with (‘‘experienced’’) and without (‘‘naive’’) prior antiretroviral (ARV) exposure at
commencement of ART at the clinic Shows that raised viral load was associated with prior
ARV experience and complete interruption of current ART(17).
In Ethiopia the factors associated with treatment failure was studied based on immunologic
and clinical criteria, showing that substance use is 1.6 times the hazard of failure compared to
those note using, Patient who were ambulatory or bed redden had about 1.81 times hazard of
failure compared with working status (HR, 1.81; 95%CI 1.25-2.60) (12),Baseline CD4 count
<)250cell/mm3(P<.028), old age group and higher educational status (P,0.001) were
significant predictors of immunological treatment failure.(18).
51.3. Conceptual framework
Fig.1 Conceptual framework.
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61.4. Justification of the study:
WHO clinical and immunological criteria have been used for monitoring and initiating ART in
resource limited settings. But many studies show that it has low sensitivity and positive
predictive value to predict virologic failure(19).Because of this, studies shows that rate of
switching is below the expected rate which leads to further increment in accumulate drug
resistance mutation and unnecessary switching of ART drug regimen. WHO 2013 ART
guideline has strongly recommended use of routine virologic monitoring for evaluation and
monitoring of ART (7). But till now viral load monitoring is not feasible in low and middle
income countries, viral load monitoring has been used for targeted groups (for those who are
suspected of treatment failure using WHO clinical and immunologic criteria). Ethiopia is one
of the nations which use targeted viral load monitoring starting recently. There is scarcity of
evidence on determinates of virologic failure in Ethiopia, therefore this study aims to assess
determinants of virologic failure among adult HIV infected client sat Gondar University
Hospital, Northwest Ethiopia.
72. Objective
To identify determinants of HIV virologic treatment failure among adult HIV infected clients
at Gondar University Hospital, Northwest Ethiopia, 2015.
83. Methods
3.1 Study design and period
Institution-based case-control study was conducted from May June /2015.
3.2 Study area:
The study was conducted in Gondar University Hospitals located in the North West of the
country. Gondar University Referral Hospital is found in Gondar Town, 748km far from
Addis Ababa to the Northwest of Ethiopia. It is a teaching hospital that acts as a referral
center for the nearby general and district hospitals as well as local health centers. Having
more than 500 inpatient beds, it gives referral services for about over 5 million inhabitants in
the northwest of Ethiopia. The HIV care services of the hospitals were initiated in 2003 and
with free ART starts in 2006 and have three clinics: Adult ART clinic, pediatric ART clinic,
and VCT clinic. The clinic has one medical doctors providing ART services, two MSc in
clinical tropical infectious disease and HIV medicine, one MPH (Master of public health), 1
health officer , 7 BSc nurse ,3 data base manager , 2 porter ,1 janitors ,6 case manager ,8
adherence supporter (people living with HIV). About12,470 HIV infected clients have been
enrolled in ART clinic of them 8220 were ever started ART and 5,138 are currently on ART.
3.3 Source of population
All HIV infected adult patients on ART who have followed up at Gondar University
Hospital from 2005- May 2015.
3.4 Study population:
All HIV infected adult clients on ART and have follow up at Gondar University Hospital for
at least 6month.
3.5 Inclusion criteria and exclusion criteria
3.5.1Inclusion criteria: All HIV infected adult (Age ≥15years) clients on ART who have
followed at Gondar University Hospitalfor≥6 month and their viral load test result is
documented.
3.5.2 Exclusion criteria: those within complete data (have no intake form, or follow-up
chart,)
93.6 Sample size determination and sampling procedure
3.6.1. Sample size determination
Sample size was determined by key predictor using Epi-info -7.
Predictor 1 -poor adherence
Predictor 2-low cd4 count at enrolment
No Key predictors Assumption OR Sample size
1 Adherence At 95% CI, 80% power. 2.8 146
2 low baseline cd4 count At 95% CI, 80% power. 7.1 110
Using this predictor’s predictor 1 has higher sample size with a total of 146 (73 cases and
73 controls). There were 175 cases and 168 controls. All 175 cases and 168 controls were
feasible for this study.
3.6.2. Sampling technique and procedure
Cases: All HIV infected patients with virologic failure (VL>1000C/ml).
Controls: All HIV infected patients without virologic failure (VL<1000C/ml).First those with
undetectable VL were selected, then those with lowest detectable VL from controls
(VL<1000C/ml) were included to get enough controls.
3.7. Variables of the study
3.7.1. Dependent variables
Virologic failure
3.7.2 Independent variables
Scio-demographic variables
Age
Sex
Residence
Marital status
Level of education
Religion
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Occupation
HIV care and anti-retroviral treatment related information
Duration since knowing HIV status
Duration (in months) since time of eligibility for ART
Duration on ART in months
Ever exposed for any ARV drugs before initiation of ART
Type of ARV drug or ART regimen experience before ART
Base line BMI
Current BMI
Current Functional status
WHO clinical stage at enrolment
History of TB disease
CPT use
Adherence status to ART
Original first line ART regimen
Change or switch of ARV regimen or individual drugs
Current ART regimen
Substance use
LABORATORY INFORMATION
Base line WBC
Current WBC
Base line Hgb/Hct
Current Hgb/Hct
Base line cd4 count
Current CD4 count
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3.8. Operational definition
Virologic failure (Cases)-viral load> 1000c/ml while on treatment at least six month
Regimen change -its modification of any or all of the initial drugs
Poor adherence - at least one “poor” or “fair” recorded by WHO definition in the follow-up
chart.
Good adherence – Good recorded by WHO definition in the follow-up chart.
Substance use- History of grade “++” and above records in the intake form.
Variables expressed as current .to show at the time of viral load test
3.9. Data collection procedures and tools
The data was collected by using a pre-tested, structured questionnaire in English version.
Data was extracted from patients chart at ART clinic .Six clinical nurses for data collector
and two BSc nurses for supervisor were involved in the study. One day intensive training
about objective of the study, data collection or extraction techniques, and variables to be
collected was given for data collectors and supervisors. At the beginning and anytime during
data collection, sufficient information and clarification was provided for the data collectors by
supervisors to come up with quality data.
3.10 Data quality control
The data collected was maintained by using standardized questionnaire and two days onsite
training was given to data collectors and supervisors in addition to this ongoing and
supportive supervision was implemented throughout the whole time of data collection. Then
the collected data was checked for its consistency and completeness before any attempt to
enter code and analyze it. Finally, Epi-Info version-7 was used to control and manage errors
resulting from data entry process.
3.11 Data processing and analysis
The collected data was cleaned, coded and entered into Epi-Info version 7, and exported to
SPSS version20 software for further analysis. Descriptive statistics was used to illustrate
the means, standard deviations, medians, ratios, rates, proportions and frequencies of the
study variables. Binary Logistic Regression was fitted. Bivariate analysis was run for each
independent variable to check the association with virologic failure. Multivariate analysis
was also considered so as to control for possible effect of confounders, adjusted odds ratio
12
with 95% confidence interval was used to determine the strength of association. Variables
with p-value ≤ 0.05 were considered as statistically significant to the dependent variable.
Hosmer and Leme show goodness of fit-test was determined (.066) and it was fit.
4. Ethical consideration
The ethical clearance was obtained from Institutional Ethical Review board of University of
Gondar. Letter of cooperation was secured from administrations of Gondar university
Hospital. After the permission obtained from ART clinic focal person, data collection
process was started. The confidentiality of patient and health care provider related data
was maintained by avoiding possible identifiers such as name of the patient, prescriber;
only numerical identification was used as a reference then after the whole data collection
process, the questionnaire was kept safe throughout the whole process of the research
work.
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5. Result and discussion
5.1. Socio-demographic characteristics of study population
From 363 HIV infected patients data was retrieved from 306 clients’ chart. The others were
not included due to incomplete data and unavailability of their charts at the time of data
collection. A total of 153 cases and 153 controls with a ratio of 1:1 were included in the
study. The mean age at starting treatment was 32 and 36 with a standard deviation of 7
and 10 year for cases & controls respectively. Majorities 82(53.6%) cases and 78(51%)
controls were females. Majority 90.2% of cases and 86.3% of controls of the study subjects
were orthodox in religion.
Regarding to marital status,  35 (22.9%)  of  cases  and  31 (20.3%)  controls were never
married  and  65 (42.5%)  of  cases  and  47 (30.7%)  of controls were married. About half
48 (31.4%) of cases and 50(32.7%) of controls unemployed  while  40  (26.1  %) of  cases
and  30 (19.6%) of  controls  were  daily laborer & most 56(36.6%) cases and 85(55.6%)
controls were secondary school and above by their education level at time of HAART
initiation. Of the study participants 20.25% have history of substance use. .The socio-
Demographic characteristics of the study participants are shown in the table 1 below.
Table 1 .Socio-demographic characteristics among cases and controls at Gondar
University Hospital 2015.
Variables category VIROLOGIC failure
Controls cases Total
N % N % N %
Age <35 years 73 47.7% 99 64.7% 172 56.2%
≥35 years 80 52.3% 54 35.3% 134 43.8%
Sex Male 74 48.4% 71 46.4% 145 47.4%
Female 78 51.0% 82 53.6% 160 52.3%
Residence urban 122 79.7% 116 75.8% 238 77.8%
rural 31 20.3% 37 24.2% 68 22.2%
Marital status never married 31 20.3% 35 22.9% 66 21.6%
married 47 30.7% 65 42.5% 112 36.6%
others 75 49.0% 53 34.6% 128 41.8%
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Educational
level
no educated 34 22.2% 42 27.5% 76 24.8%
primary 34 22.2% 55 35.9% 89 29.1%
secondary 85 55.6% 56 36.6% 141 46.1%
Religion Orthodox 132 86.3% 138 90.2% 270 88.2%
Others 21 13.7% 15 9.8% 36 11.8%
Occupation Not employed 50 32.7% 48 31.4% 98 32.0%
Employed 42 27.5% 24 15.7% 66 21.6%
self employed 31 20.3% 41 26.8% 72 23.5%
daily laborer 30 19.6% 40 26.1% 70 22.9%
5.2. Clinical characteristics
According to WHO clinical staging majority of participants 121(79.1%) was classified as
stage III&IV; at enrolment. Tuberculosis was occurred in 33(26.1%) cases 20(13.1)controls
and, 40(26.1%), cases 44(28.8%) controls before and after, starting ART respectively. most
of the study participants276 (91.3%) were enrolled to cotri-moxazol prophylaxis therapy
when was indicated. The BMI of the study participants were below 16.5kg/m2 in 22(14.4%)
cases and 18(11.8%) controls and 28(18.3)of cases and 16(10.5) at the beginning of ART
and currently respectively. Most of the study participants 47(31.3%) cases and 78(51%)
controls were started their first line ART with AZT based regimen and 86(56.2%) of cases
and 90 (58.8%) of controls were on AZT based regimen.D4T based regimen was
insignificant (<5) at the time of treatment failure diagnosis in both groups .nearly half of the
study participants 47.4%(47.7% of cases and 47.1% of controls has history of change their
ART regimen or individual ARV medication. Regarding to adherence half of cases76
(49.7%) and 12(7.8%) controls had history of poor adherence. Most of the study subjects
109(71.2%) of cases and 75(49%) of controls were on HAART for more than 48 months.
The clinical data of study subjects is shown in the table below.
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Table 2: clinical and ARV medication related information among cases and controls
at Gondar University Hospital 2015
Variables Category Virologic failure
Control Cases Total
N % N % N l %
Baseline BMI <16.5 18 11.8% 22 14.4% 40 13.1%
16.5-18.49 49 32.2% 48 31.4% 97 31.7%
≥18.5 85 55.9% 83 54.2% 168 54.9%
Current BMI <16.5 16 10.5% 28 18.3% 44 14.4%
16.5-18.49 28 18.4% 27 17.6% 55 18.0%
≥18.5 108 71.1% 98 64.1% 206 67.3%
WHO clinical stage stage I & II 42 27.5% 32 20.9% 74 24.2%
stage II &
IV
111 72.5% 121 79.1% 232 75.8%
ADHERENCECAT Good 141 92.2% 77 50.3% 218 71.2%
Poor 12 7.8% 76 49.7% 88 28.8%
History of TB No TB 89 58.2% 80 52.3% 169 55.2%
Before
ART
20 13.1% 33 21.6% 53 17.3%
After ART 44 28.8% 40 26.1% 84 27.5%
CPT When
indicated
NO 14 9.2% 11 7.2% 25 8.2%
Yes 139 90.8% 142 92.8% 281 91.8%
First line ART
regimen
D4T Based 38 24.8% 64 42.7% 102 33.3%
AZT Based 78 51.0% 47 31.3% 125 40.8%
TDF
Based
37 24.2% 39 26.0% 76 24.8%
Change of ARV
regimen or
individual drugs
No 81 52.9% 80 52.3% 161 52.6%
Yes 72 47.1% 73 47.7% 145 47.4%
ART Regimen at
the time of VL test
AZT Based 90 58.8% 86 56.2% 176 57.5%
TDF
Based
63 41.2% 67 43.8% 130 42.5%
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Duration with HIV 6-25 28 18.3% 9 5.9% 37 12.1%
25-48 46 30.1% 30 19.6% 76 24.8%
≥48 79 51.6% 114 74.5% 193 63.1%
ARTDURATION 6-25 38 24.8% 13 8.5% 51 16.7%
25-48 40 26.1% 31 20.3% 71 23.2%
≥48 75 49.0% 109 71.2% 184 60.1%
Substance use NO 118 77.1% 126 82.3% 244 79.7%
YES 35 22.9% 27 17.6% 62 20.3%
Total 153 100% 153 100% 306 100%
Laboratory information
Most of the study participants 120 (78.9%), 73(48.4%) controls and 135 (88.2%),
125(81.7%) cases had baseline and current CD4 count   below 200cells/mm3
respectively. Only one- third 36(23.8%) controls and 56(37.8%) of cases of the study
participants had current WBC count of<4,000cells/mm3.
Majority 127(84.1%) of controls and 113(75.8%) of cases had current hemoglobin of
>112g/dl.
The laboratory information is shown in the table below.
Table 3. Laboratory information among cases and controls at Gondar university
Hospital 2015
Variables category Virologic failure
Control Cases Total
N % N % N %
current WBC <4,000c/mm3 36 23.8% 56 37.8% 92 30.8%
>4,000c/mm3 115 76.2% 92 62.2% 207 69.2%
Current
Hemoglobin
<12g/dl 24 15.9% 36 24.2% 60 20.0%
>12g/dl 127 84.1% 113 75.8% 240 80.0%
Baseline CD4
count
<200c/mm3 120 78.9% 135 88.2% 255 83.6%
>200c/mm3 32 21.1% 18 11.8% 50 16.4%
Current CD4
count
<200c/mm3 74 48.4% 125 81.7% 199 65.0%
>200c/mm3 79 51.6% 28 18.3% 107 35.0%
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5.3. Factors associated with HIV virologic treatment failure
In a bivariate analysis with P value < 0.2, age, marital status, education, occupation,
adherence, TB Diseases, WHO clinical stage, current BMI, first line ART, duration on ART,
duration with HIV, baseline and current CD4 count ,current WBC count, current
Hemoglobin level, were associated with antiretroviral virologic treatment failure.
Table 4. Factors associated with ART treatment failure Gondar university
hospital2015.
variables Category Control   NO     % Cases NO       % p COR 95%CI
Low up
Age <35 years 73 47.7% 99 64.7% .003 2.009 1.27 3.18
≥35 years 80 52.3% 54 35.3% .026 .675
Marital status Never married 31 20.3% 35 22.9% .032
Married 47 30.7% 65 42.5% .516 1.225 .664 2.26
Others 75 49.0% 53 34.6% .124 .626 .344 1.14
Educational
level
no educated 34 22.2% 42 27.5% .003
Primary 34 22.2% 55 35.9% .029 1.875 1.07 3.3
Secondary 85 55.6% 56 36.6% .001 2.455 1.42 4.23
Occupation Not employed 50 32.7% 48 31.4% .055
Employed 42 27.5% 24 15.7% .112 .595 .314 1.13
self employed 31 20.3% 41 26.8% .305 1.378 .747 2.54
daily laborer 30 19.6% 40 26.1% .297 1.389 .749 2.57
WHO clinical
stage
stage I & II 42 27.5% 32 20.9%
stage II & IV 111 72.5% 121 79.1% .183 1.431 .845 2.42
ADHERENCE Good 141 92.2% 77 50.3%
Poor 12 7.8% 76 49.7% 000 12.45 6.26 24.9
History of TB No TB 89 58.2% 80 52.3% .150
Before ART 20 13.1% 33 21.6% .060 1.836 .976 3.45
After ART 44 28.8% 40 26.1% .966 1.011 .599 1.71
First line ART
regimen
D4T Based 38 24.8% 64 42.7% .000 .358 .208 .614
AZT Based 78 51.0% 47 31.3% .128 .626 .342 1.1
TDF Based 37 24.2% 39 26.0% .001
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ARTDURATI
ON
6-25 38 24.8% 13 8.5% .000
25-48 40 26.1% 31 20.3% .041 2.265 1.033 4.968
≥48 75 49.0% 109 71.2% .000 4.248 2.120 8.52
Current BMI <16.5 16 10.5% 28 18.3% 056 1.929 .985 3.78
16.5-18.49 28 18.4% 27 17.6% .841 1.063 .586 1.97
≥18.5 108 71.1% 98 64.1% .158
current WBC <4,000c/mm3 36 23.8% 56 37.8% .009 1.944 1.18 3.21
≥4,001c/mm3 115 76.2% 92 62.2%
Current
Hemoglobin
<12g/dl 24 15.9% 36 24.2% .075 1.686 .948 2.99
≥12.1g/dl 127 84.1% 113 75.8%
Baseline CD4
count
<200c/mm3 120 78.9% 135 88.2% .030 2.000 1.07 3.75
≥201c/mm3 32 21.1% 18 11.8%
Current CD4
count
<200c/mm3 74 48.4% 125 81.7% .000 4.766 2.839 8.0
≥201c/mm3 79 51.6% 28 18.3%
Others (Muslim &protestant)
Multivariable analyses
All variables associated with first line treatment failure in the bivariate analysis with P value
<0.2 were entered in a multivariable logistic regression analysis. Finally, age, marital status,
history of poor adherence, current CD4 count <200 cell/mm3 and duration on ART were
independently associated with antiretroviral virologic treatment failure.
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Table 5. Independent predictor’s of ART virologic treatment failure in Gondar university
hospital 2015.
Variables Category Control
NO    %
Cases
NO      %
P COR 95%CI
P
AOR 95%CI
L upp
Age <35 years 73(47.7%) 99 64.7% .03 2(1.27-3.18) .04 2.52(1.33-4.77)
≥35 years 80(52.3%) 54 35.3% .026 .67 1
Marital
status
never
married
31 20.3% 35 22.9% .032 1
Married 47 30.7% 65 42.5% .516 1.23(.66-.26)
Others 75 49.0% 53 34.6% .124 .63(.34-1.14) .04 2.1(1.10-4.11)
Educationa
l level
no
educated
34 22.2% 42 27.5% .003
Primary 34 22.2% 55 35.9% .029 1.88 1.07 3.23
Secondary 85 55.6% 56 36.6% .001 2.56 1.42 4.23
Occupation
Not
employed
50 32.7% 48 31.4% .055
Employed 42 27.5% 24 15.7% .112 .59 .31 1.13
self
employed
31 20.3% 41 26.8% .305 1.38 .75 2.54
daily
laborer
30 19.6% 40 26.1% .29 1.39 .75 2.57
WHO
clinical
stage
stage I & II 42 27.5% 32 20.9%
stage II &
IV
111 72.5% 121 79.1% .18 1.43 .84 2.42
ADHEREN
CE
Good 141 92.2% 77 50.3% 1
Poor 12 7.8% 76 49.7% 000 12.4 6.26 24.9 00 15.8(6.9-36.5)
History of
TB
No TB 89 58.2% 80 52.3% .150
Before ART 20 13.1% 33 21.6% .060 1.84 .976 3.45
After ART 44 28.8% 40 26.1% .966 1.01 .599 1.71
First line
ART
regimen
D4T Based 38 24.8% 64 42.7% .000 .358 .208 .614
AZT Based 78 51.0% 47 31.3% .128 .626 .342 1.14
TDF Based 37 24.2% 39 26.0% .001
Duration 6-25 38 24.8% 13 8.5% .000 1
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COR (crud odds ratio), AOR (adjusted for other variables), CI (confidence interval)
on ART 25-48 40 26.1% 31 20.3% .041 2.26 1.03 4.97 .04 3(1.1-8.4)
≥48 75 49.0% 109 71.2% .000 4.25 2.12 8.52 00 6.7(2.7-16.6)
Current
BMI
<16.5 16 10.5% 28 18.3% 056 1.92 .98 3.78
16.5-18.49 28 18.4% 27 17.6% .841 1.06 .58 1.97
≥18.5 108 71.1% 98 64.1% .158
current
WBC
<4,000c/mm3 36 23.8% 56 37.8% .01 1.94 1.18 3.20
≥4,000c/mm3 115 76.2% 92 62.2%
Current
Hemoglobin
<12g/dl 24 15.9% 36 24.2% .075 1.68 .95 2.99
≥12g/dl 127 84.1% 113 75.8%
Baseline
CD4 count
<200c/mm3 120 78.9% 135 88.2% .030 2.00 1.07 3.75
≥200c/mm3 32 21.1% 18 11.8%
Current
CD4 count
<200c/mm3 74 48.4% 125 81.7% .000 4.77 2.84 8.00 00 9.03(4.4-18.5)
≥200c/mm3 79 51.6% 28 18.3%
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6. Discussion
The study has provided an opportunity to find out determinants of first line antiretroviral
virologic treatment failure which is globally a very serious challenge for antiretroviral treatment
program. In the study, risk factors antiretroviral virologic treatment failure was determined in
adult HIV-infected population in Gondar university Hospital. Among this factors recent CD4
count <200 cell/µl was significantly associated with antiretroviral virologic treatment failure.
Patients with recent CD4 count below 200cell/µl failed9 times than that of with CD4 count
of>200 cell/µl with 95% CI (4.4-18.5) The result is consistent with other study done in central
Cameron yawn die; a recent CD4 count less than 200 cells per microliter increased the odds
of failure more than 7.4 folds this could be presence of drug resistant virus at initiation of ART
[16].
Patients who have history of poor adherence were failed15.8 times when compared with
those who have no history of poor adherence with 95% (CI 6.9 to 36.5). The result is
comparable with a study done in Cameron; the odds of treatment failure were more than 12.8
folds for Patients who had poor adherence [16]. The very high risk of first line antiretroviral
treatment failure in the study in patients with unplanned interruptions to therapy raises a
concern that the failure to stagger ART cessation may be contributing to subsequent
treatment failure which is consistent with several previous reports [5, 8].Another risk factors
determined were age <35years with adjusted odds ratio of 2.52 more likely to develop ART
virologic treatment failure when compared with age greeter than 35 years with (CI-1.33 to
4.77),this is similar with study done in South Africa and France shows that age less than 30
years was associated with ART virologic treatment failure(7,15).this is probably due to loose
of hop and stress which leads to poor adherence to ART medication. Another factor which
significantly associated was long duration on ART. The odds of treatment failure in those for
25-48 months of treatment was 3 times when compared with   less than 25 months of
treatment with CI(1.1-8.4) and 6 ,7times more likely in those with greater than 48 months of
treatment with CI (2.7-16.6). This study is similar with studies in Lesotho (16).This is probably
due to drug resistance and other opportunistic infections. The other associated factor in this
study is marital status those who separated, divorced, and widowed were more likely to
develop treatment failure 2.1times when compared with never married with CI (1.10-4.11).
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These in line with a study done in Gabon divorced were at high risk of ART virologic
treatment failure (14). This is probably due to lack of social support and instability of family.
Strengths
 It is done in better and well organized ART clinic where medical records and data is well
managed.
 The data was collected by appropriate trained nurse who know the terminologies across
the data collection process.
Limitations
Poorly recorded clinical information during the follow up period affects to explore additional
determinant factors.
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7. Conclusion
Majorities 82(53.6%) cases and 78(51%) controls were females. Majority 90.2% of cases and
86.3% of controls of the study subjects were orthodox in religion. Regarding to marital status,
35 (22.9%)  of  cases  and  31 (20.3%)  controls were never married  and  65 (42.5%)  of
cases  and  47 (30.7%)  of controls were married. According to WHO clinical staging majority
of participants 121(79.1%) was classified as stage III&IV; at enrolment. Tuberculosis was
occurred in 33 (26.1%) cases 20(13.1) controls and, 40(26.1%), cases 44(28.8%) controls
before and after, starting ART respectively
Most of the study participants120 (78.9%), 73(48.4%) controls and135 (88.2%), 125(81.7%)
cases had baseline and current CD4 count   below 200cells/mm3 respectively
The independent predictors for antiretroviral virologic treatment failure were; recent cd4 count
lower than 200 cell/µl, history of poor adherence for ART, age<35 years, marital status and
long duration on ART. Based on the findings of the study the following recommendation is
forwarded.
8. Recommendations
Health professionals should pay attention to give strict adherence counseling for patients and
monitoring routine CD4 count to monitor ART treatment response and to diagnose early
treatment failure.
Patients should take their medication as prescribed and consult their clinician when needed.
Government body should monitor and evaluate   recordings system and improve recording
system.
Finally further study on patients follow up and quality of care should be done in the future.
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10. Annexes
Annex I: Information sheet
Title of the research project: determinants of HIV virologic treatment failure at Gondar
university Hospital, North west Ethiopia 2015
Principal Investigator: Belete Bayu
Advisors:
Mr. Amare Tariku (MSc)
Dr. Abera Balcha
Name of the organization: University of Gondar, Collage of Medicine and Health Sciences,
Department of internal medicine
Sponsor: Amhara regional health bureau
Introduction
This checklist is prepared for the collection of socio-demographic, HIV care and antiretroviral
treatment and laboratory related information to determine predictors of ART virologic failure
among Adult HIV infected clients at University of Gondar hospital. All this information will be
retrieved from the clients ART and pre ART registration book and from individual patient card
without mentioning the name of the clients. This information will be collected by health care
providers working in the ART clinic at Gondar university Hospital.
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Annex II: Questionnaire
General information
1 MRN/HMISNO:
2 UAN
3 Appointment date 1—---------------------
2---------------------------
4 Telephone number-or recent contact address
to tack patient
Socio-demographic information
1 Age
2 Sex Male
Female
1
2
3 Residence write specific
location residence information
4 Marital status Never married
Married including de facto
Separated
Divorced
Widow/widower
1
2
3
4
5
5 Level of education No education
Primary
Secondary
Tertiary
1
2
3
4
6 Religion Orthodox
Muslim
Protestant
Catholic
Other specify-----------------------
1
2
3
4
5
28
7 Occupation
Note : a house wife with no
income will fall under
unemployed see HIV/ART
intake form
Not employed
Civil servant/govt employee
Farmer
Merchant/retailer
Daily laborer/migrant worker
Other specify-------------------
1
2
3
4
5
6
HIV care and anti-retroviral treatment related information
1 Write duration (in months )since time of
HIV TEST confirmed
Note: please refer ART intake & follow-
up form
1.date of HIV test (dd/mm/yyyy
____/________/______
2. months_________________
2 Write duration (in months )since time of
eligibility for  ART
Note: please refer ART intake & follow-
up form
1.Date of eligibility for ART
_____/________/_______
2.months_________
3 Duration on ART in months
Note: please refer ART intake & follow-
up form
1. Date of eligibility for ART
____/________/_______
2. Months__________
4 Ever exposed for any ARV drugs before
initiation of ART. Note :consider all
exposers to ART before ART is started
based on national ART guideline
Yes
No
1
2
5 If exposed which ARV drug or ART
regimen
Note: please refer ART intake & follow-
up form or PMTCT code on ART follow-
up card
A-combination ART (HAART) but
stopped
B- PMTCT prophylaxis (sd-NVP,
AZT, or combination ARV)
C-Prophylaxis other than for
PMTCT (PEP, prep)
D-Others specify__________
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6 Base line BMI. Note: see at “zero” month Kilogram/meter square________
7 Current BMI. note: write BMI at last visit Kilogram/meter square________
8 Ever pregnant  while taking ART 1-yes
2-no
3-note applicable(male sex)
1
2
3
9 Current functional status
Note: if client has different functional
assessment result /category  please
write the most recent one
W-working
A –Ambulatory
B-Bed-ridden
1
2
3
10 WHO Clinical stage of diseases at
enrolment
Note: write WHO clinical stage of AIDS
at start of  ART as written on the ART
intake or follow up form
Stage I
Stage II
Stage III
Stage IV
1
2
3
4
11 Screened for tuberculosis in the last 6
months( i.e. while taking ART)
Yes, positive
Yes, negative for TB
1
2
12 If screened for TB is hey/she on
treatment or prophylaxis? note:
applicable to the last six months (i.e.
while taking ART)
On treatment for TB (TB Rx)
On INH or prophylaxis for TB
NO prophylaxis or treatment
1
2
3
13 Ever enrolled to cotrimoxazole (TMP-
SMX) Preventive prophylaxis in the last
6 months Note: make “yes” if drug doses
or duration is documented .if started in
the last 6 months but stopped mark yes
Yes
No
1
2
14 Current adherence to ART Status
Note: if client has different adherence
assessment results /category please
write the most recent one (among those
documented in the last 6 months)
G-Good
F-Fair
P-Poor
1
2
3
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15 Write the original first line ART initiated
at zero month )enrolment to ART
program
Note: write correct and original first line
ART. For transfer ins (TI) write the
combination of ART initiated for the first
time at referring clinic (here please circle
on exact same regimen the patient has
been started the first time check only
one. If you can’t   identify a particular
drug from the below drug list ,please
make on “other “ and write the name of
every drug  on the blank space
.otherwise, please do not write codes or
abbreviations
First line ART
1a=d4T+3TC+NVP
1b=d4T-3TC+EFV
1C=ZDV+3TC+NVP
1d=ZDV+3TC+EFV
1e=TDF+3TC+EFV
1f=TDF+3TC+NVP
Alternative or second line ART
2a=ABC+ddI+LPV/r
2b=TDF+3TC+LPV/r
2c=ZDV+3TC+LPV/r
2d=ZDV+ABC+LPV/r
Others specify___________
1
2
3
4
5
6
7
8
9
10
11
16 Any change or switch of ARV regimen or
individual drugs
Note: change in manufacturer or brand
of a drug is not considered switch or
change.
Yes, regimen /drug is changed
NO (it is the same regimen & drug)
1
2
17 Write the current ART  regimen
(Here please circle on exact same
regimen the patient is currently taking
or has been taking in the previous three
months .check only one. If you can’t
identify a particular drug from the below
drug list ,please make on “other “ and
write the name of every drug  on the
blank space .otherwise, please do not
write codes or abbreviations
First line ART
1a=d4T+3TC+NVP
1b=d4T-3TC+EFV
1C=ZDV+3TC+NVP
1d=ZDV+3TC+EFV
1e=TDF+3TC+EFV
1f=TDF+3TC+NVP
Alternative or second line ART
2a=ABC+ddI+LPV/r
2b=TDF+3TC+LPV/r
2c=ZDV+3TC+LPV/r
2d=ZDV+ABC+LPV/r
Others specify___________
1
2
3
4
5
6
7
8
9
10
11
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18 Write all reasons for change or switch of
ARV regimen or individual drug. first all
option /choices
Refer codes or “reason for change “on
the back of national ART follow-up chart
or intake form and progress sheet.
Important :consider recent changes of
regimen due to staved in phase-out
program as toxicity of drug”
Do not guess reasons; consult
consultant or ART physician.
Toxicity of drug
Yes
No
Pregnancy
Yes
No
Drug stock out
Yes
No
Other please
specify___________________
1
2
1
2
1
2
3
19 Any opportunistic diseases in the last
six months while on ART
Note: please document new or recurrent
WHO stage IV conditions and the
following stage III conditions pulmonary
TB sever bacterial infection (source
national ART guideline)
Note: please use abbreviations that
match the list on the back of national
ART follow up form.
PCP, pneumocystiscarini
pneumonia
BP ,sever bacterial pneumonia
CT, CNS toxoplasmosis
CM, Cryptococcal  meningitis
PTB, pulmonary tuberculosis
ETB, exta-plumonary TB, or
disseminated TB(other than lymph
nod TB)
None or OI is not recorded
Other (specify)
1
2
3
4
5
6
7
8
LABORATORY INFORMATION
1 Base line WBC count before /at initiation of
ART
Note : write the test result closes to ART
initiation date (+-30 days)
WBC_____________________/m
m3
Note available
000
2 Current WBC count
Note: when there are different test results
take the most recent in the last six months
as current
WBC__________________/mm3
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3 Base line hemoglobin result before /at
initiation of ART
Note: write the test result close to  ART
initiation date (+-30 days)
Note: when hemoglobin is not available fill
in hematocrit
Hgb____________________mg/dl
Hct_____________________%
Note available on record
000
4 Current hemoglobin
Note: take the most recent hemoglobin
result in the last 6 month as current
Hgb____________________mg/dl
Hct____________________%
5 Base line cd4 test result before start of ART
Note: write the test result closest to ART
initiation date(+-30 days)
Cd4__________________/mm3
Not available on record 000
6 Peak cd4 tests while on ART
Note: record the highest cd4 count ever
recorded. If different from the one recorded
on TFSS, write the recent result.
______________________/mm3
7 Current  cd4 test result
Note: record the recent result (<-6months).if
different from the one recorded on TFSS
write the recent result.
Cd4___________________/mm3
8 Base line viral load test
Note: record any  viral load test done prior
to 90 days (three months)
_____________________c/ml
Note available on record 000
9 Current viral load test
Note: record the most recent HIV viral load
result <-90) days and the test date from
records (charts or laboratory register)
VL___________________C/ml
Date(DD/MM/YYYY)
______/_______/________
Complete forms will be submitted to hospital HIV case team leader or CEO
Audit completed by__________________________________signature_____________
Audit supervised by__________________________________signature_____________
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